United States

Idiopathic intracranial hypertension (IIH) is a pathologic elevation of the intracranial pressure (ICP) that can lead to blindness, cognitive decline, debilitating headaches, and distressing pulsatile tinnitus (PT). IIH most commonly affects overweight women of childbearing age, and has an incidence of 20 in 100,000 in this patient cohort, and is becoming even more prevalent with the increasing obesity epidemic. We are also noticing a rise in childhood IIH as the childhood obesity epidemic similarly increases. MRI/MRV imaging demonstrates focal stenoses of the transverse dural venous sinus (TS) in up to 93% of patients with IIH versus 6.8% of asymptomatic control subjects. TS stenoses are critical to the pathophysiology of IIH. While the inciting event of IIH is unknown, it is apparent that TS stenoses are a critical part of a positive feedback loop, and disrupting TS stenoses with venous sinus stenting (VSS) can break the vicious cycle and cure IIH. The aim of this presentation is to review the pathophysiology underlying IIH and the role VSS can play in treating IIH patients. The indications of VSS, success rates, complications rates and revision surgery rates are reviewed in the context of other available surgical therapies including shunting, optic nerve sheath fenestration, and bariatric surgery.

IPSO 2021

Venous sinus stenting for idiopathic intracranial hypertension

venous infarction/venous sinus thrombosis

Welcome to the **largest national, multi-specialty research** event featuring research from nearly 700 medical students, residents, fellows, and international medical graduates.

Use the buttons below or navigation menu to access the event.
 


[![](https://assets.underline.io/uploads/markdown_image/1/image/3e33a8c754cc49610b30950617d813e7.png)](https://underline.io/events/434/sessions?searchGroup=all)
 
[![](https://assets.underline.io/uploads/markdown_image/1/image/551404d429c4e274f9a54cbdd7081918.png)](https://underline.io/events/434/posters?searchGroup=all)
 
[![](https://assets.underline.io/uploads/markdown_image/1/image/677d92f566b880cebd36905fc738fc10.png)](https://underline.io/events/434/lounge)
 
[![](https://assets.underline.io/uploads/markdown_image/1/image/c7392833c7261c3874c5b43fa2f4df19.png)](https://underline.io/events/434/help-desk)
 

#### Event Details

The 2023 American Medical Association Research Challenge includes a poster symposium hall and a semifinals hall with the top scored research. **Log in at any time throughout the event to:**

* **View posters and presentations** on a variety of topics and specialties
* **Score posters in the semifinals** to help decide the top five finalists (AMA member exclusive opportunity)
* **Connect with participants** and provide feedback to help advance their research
* **Attend education sessions** with physician experts on key research topics

At the conclusion of this event, the AMA will announce the top five finalists who will advance to the AMA Research Challenge finals, present their research to an elite panel of judges, and compete to win a $10,000 grand prize sponsored by Laurel Road. 

### Grand Prize Sponsor

AMA would like to thank Laurel Road for sponsoring a $10,000 grand prize for the winner of the AMA Research Challenge. Laurel Road is not involved in the judging or scoring process to select the winner. The winner will be announced on February 4, 2024 during the AMA Research Challenge finals. Payment of the grand prize will be directly from Laurel Road. See the AMA Research Challenge Official Rules for terms and conditions.

![](https://assets.underline.io/uploads/markdown_image/1/image/611e331d4a0eba0920f240cfc04b4d77.png)

**There is no registration fee for this event! **

Register to explore research in a variety of topics. AMA members get exclusive access to score posters in the semifinals.

**Please use this link [here](https://www.ama-assn.org/about/events/ama-research-challenge) to register for free.**

Registration Is Required

AMA Research Challenge 2023

Join the AMA Research Challenge poster symposium and semifinals to explore top research posters, score posters in the semifinals (an AMA member exclusive opportunity) and attend education sessions with experienced physicians to learn tips to advance your research and career. 

poster

**[Download Full Agenda](https://drive.google.com/file/d/1Dm9lJyTfJrvd7-StaHFmUmhXC-J_UgTj/view?usp=sharing)**

Dear IPSO Virtual Conference Attendees:

Welcome to IPSO’s first-ever conference! We are delighted to bring together experts from multiple disciplines and six continents to provide a diverse perspective on pediatric cerebrovascular disease. 

A few quick words about what to expect. Two important goals of this conference are to (1) foster a sense of community and (2) identify global priorities for our field. Hence, the program includes short presentations on an array of clinical controversies and dedicates more time to panel discussions with a live chat function so that everyone can participate. We are excited to announce IPSO is able to offer 8.75 CME units for the virtual conference. If you would like to claim CME credits, please email <membership@internationalpediatricstroke.org>. 

We want to hear from you! Planning for the [IPSO Founding Members’ Congress](https://internationalpediatricstroke.org/2022-congress/) in Vienna, April 24-26, 2022, will commence as soon as the Virtual Conference ends. Let us know your priorities through the live chat function, via email, or by submitting a symposium idea. Based on your input, the Scientific Program Committee will select the topics that we will address in greater depth when we meet again in the spring.

We hope you find the Virtual Conference both interesting and educational, and hope to see you in person in Vienna, or at another IPSO meeting in the future. 

Warm regards,

Heather Fullerton, IPSO President

Adam Kirton, IPSO Vice-President

Lori Jordan, IPSO Secretary & Treasurer


![](https://assets.underline.io/uploads/markdown_image/1/image/1c71a0aebc49947c923a7920d9f28857.jpg)



 
 
 


 



*Header Photo Credit: Helen Carlson, Ph.D, Alberta Children's Hospital*

To access IPSO 2021, you must pre-register for the conference.  Instructions on how to access the event will be provided directly to attendees and included on the IPSO 2021 conference website. [Register now](https://internationalpediatricstroke.org/2021-congress/registration/).

Welcome to the first IPSO Virtual Conference. The mission of the virtual conference is to unify the global community of professionals engaged in research and clinical care for children with cerebrovascular diseases, and chart a path forward for multinational, multidisciplinary efforts. Please go here to access the virtual conference platform- <a href="https://underline.io/events/157/reception">Reception page</a>.

Medical and surgical management of moyamoya - Sudhakar Vadivelu

Moyamoya Research in Japan - Miki Fujimura

Moyamoya Research in Japan - Kikutaro Tokairin

Novel Oral Anticoagulants (NOACs) for pediatric stroke prevention - Marcela Torres

Controversies in sickle cell disease - Fenella Kirkham

Controversies in sickle cell disease - Pat McGann

Lessons & challenges from the pandemic - Lauren Beslow

Reperfusion therapy (thrombolysis) is widely used in adults, but the extrapolation of the method to children is impossible because of the age-related features of the hemostasis system and metabolism in children. Aim. Еvaluate the efficacy and safety of thrombolysis in children with arterial ischemic stroke (AIS). Materials: From March 2018 to November 2019, ten children with stroke underwent thrombolysis. Criteria recommended by Thrombolysis in Pediatric Stroke were taken as criteria for selecting patients for thrombolysis. Ten children from 3.5 to 16 years old (average age -10.3g) were included. Results: Patients with stroke had: thrombophilia-2, autoimmune hemolytic anemia-1, polyangiitis-1, Epstein-Barr virus infection-1, transient nocturnal hemoglobinuria with aplastic anemia-1, arteropahty-2, Kavasaki disease -2. The severity of stroke was from 9 to 24 points by PedNIHSS (average -15.8b). The stroke was confirmed by MRI-angiography. The time of start of thrombolysis was from 4 to 10 hours (average 6.3 hours). Thrombolysis in all cases was carried out by the recombinant human tissue plasminogen activator - alteplase. None of our patients had any complications (hemorrhage). MRI control of the efficacy of thrombolysis was carried out after 6-8 hours. In 5 cases, the effect was pronounced: the change on the PedNIHSS scale: from 9 to 2b, from 22 to 8, from 9 to 4, from 10 to 2, from 15 to 6; in five - ineffective: 1- with the infection, two with progressive arteriopathy, one - with polyangiitis, one- transient nocturnal hemoglobinuria with aplastic anemia. A child with polyangiitis and AIS in the basilar artery was thromboextracted after ineffective thrombolysis. Conclusion: In our center, we considered as potential candidates for thrombolysis of all children with AIS who arrived at the clinic no later than 12 hours from the onset of the disease. In our observation, the effectiveness of thrombolysis depended on the etiology of AIS.

Thrombolysis in children and adolescents with ischemic stroke. Experience of the Primary Pediatric Stroke Center in Moscow

We evaluated 22 children presenting with "posterior circulation" symptoms with provocative digital catheter angiography with neck rotation and observed "dynamic arterial compression" (DAC) involving the V3 segment where C1 rotates on C2 in 10 children. 17 (14M) presented with stroke, 12 had vertebral artery (VA) dissection, with 3 having "presumed dissection" as stroke mechanism. DAC of the VA was found in 10 (9M), all with observed VA dissection. These 10 were treated with surgical fusion at C1/C2. None had recurrent stroke post op. The 7 without DAC were not treated surgically. AIS etiologies: dissection 2, presumed dissection 3, basilar artery occlusion 1, cardioembolic 1. We presume that in 4 of these 7, supraphysiologic rotation from trauma led to VA dissection but they were not surgically treated as there was no DAC under "normal" degrees of rotation. In 3/7, one VA was either occluded or was unable to be catheterized so could not be assessed. 5 other children (4M) presented with posterior circulation symptoms but did not have AIS. Provocative angiography and did not demonstrate DAC. Etiologies: post-concussion syndrome, opiate ingestion, MELAS, vertebral pseudoaneurysm, and psychogenic. Our observations, particularly of bilateral VA dissection at V3 in 3 children, with high incidence of DAC at this same region suggests that DAC may lead to VA dissection. Our observation of children without DAC demonstrates that such compression is not normal physiology. DAC may be an age or stage of growth-related RF for VA dissection. Other factors, such as arterial wall composition (collagen vascular genetic variants) and hypercoagulable states may also contribute. Our protocol for suspected posterior circulation stroke includes c-spine immobilization, evaluation by provocative digital catheter angiography, with strong consideration for surgical intervention in those demonstrating DAC.

Is Cupid at risk of Bowhunter's Syndrome? Vertebral artery compression with neck rotation in children with posterior circulation symptoms

Importance: Randomized clinical trials have shown the efficacy of thrombectomy of large intracranial vessel occlusions in adults; however, any association of therapy with clinical outcomes in children is unknown. OBJECTIVE: To evaluate the use of endovascular recanalization in pediatric patients with arterial ischemic stroke. DESIGN: This retrospective, multicenter cohort study, conducted from January 1, 2000, to December 31, 2018, analyzed the databases from 27 stroke centers in Europe and the United States. Included were all pediatric patients (<18 years) with ischemic stroke who underwent endovascular recanalization. RESULTS: Seventy-three children from 27 participating stroke centers were included. Median age was 11.3 years (interquartile range [IQR], 7.0-15.0); 37 patients (51%) were boys, and 36 patients (49%) were girls. Sixty-three children (86%) received treatment for anterior circulation occlusion and 10 patients (14%) received treatment for posterior circulation occlusion; 16 patients (22%) received concomitant intravenous thrombolysis. Neurologic outcome improved from a median PedNIHSS score of 14.0 (IQR, 9.2-20.0) at admission to 4.0 (IQR, 2.0-7.3) at day 7. Median mRS score was 1.0 (IQR, 0-1.6) at 6 months and 1.0 (IQR, 0-1.0) at 24 months. One patient (1%) developed a postinterventional bleeding complication and 4 patients (5%) developed transient peri-interventional vasospasm. The proportion of symptomatic intracerebral hemorrhage events in the HERMES meta-analysis of trials with adults was 2.79 (95% CI, 0.42-6.66) and in Save ChildS was 1.37 (95% CI, 0.03-7.40). CONCLUSIONS: The results of this study suggest that the safety profile of thrombectomy in childhood stroke does not differ from the safety profile in randomized clinical trials for adults; most of the treated children had favorable neurologic outcomes. This study may support clinicians' practice of off-label thrombectomy in childhood stroke in the absence of high-level evidence.

Downloads

Next from IPSO 2021

Medical and surgical management of moyamoya - Sudhakar Vadivelu

Similar lecture

Neurological Sequelae in Idiopathic Intracranial Hypertension and COVID-19 Patients: A Novel Case Series

.css-70qvj9{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;}Downloads

Next from IPSO 2021

Medical and surgical management of moyamoya - Sudhakar Vadivelu

Similar lecture

Neurological Sequelae in Idiopathic Intracranial Hypertension and COVID-19 Patients: A Novel Case Series

Downloads